Haibo Bing
Photodynamic Diagnosis (PDD) and Photodynamic Therapy (PDT) have emerged as powerful tools in cancer management, offering a minimally invasive approach for tumor detection and treatment. These techniques rely on the use of Photosensitizers (PS) that, upon activation by specific wavelengths of light, generate Reactive Oxygen Species (ROS) capable of inducing selective tumor cell destruction. The effectiveness of PDD and PDT is largely dependent on the choice of molecular targets and bioconjugation strategies, which enhance the specificity, bioavailability, and therapeutic efficacy of the photosensitizers. One of the primary challenges in photodynamic therapy is achieving selective accumulation of the photosensitizer in malignant tissues while minimizing damage to healthy cells. To address this, emerging molecular targets have been identified based on tumor-specific biomarkers, overexpressed receptors, and the unique tumor microenvironment. Cell surface receptors such as Epidermal Growth Factor Receptor (EGFR), Folate Receptor (FR), and integrins have been widely studied for their role in tumor proliferation and are now being exploited for targeted PS delivery.
PDFShare this article
Journal of Genetics and DNA Research received 3 citations as per Google Scholar report
